DSC_6697
Thursday, April 2, 2026
20.8
C
Bengaluru
Hot topics
When Influence Meets Accountability: Why India Wants Wellness Gurus to Show Their Credentials
India’s wellness economy is booming—nutraceuticals, supplements, and alternative therapies...
What about Indian Pharma?
Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
Dr. Tarun Gupta Tribute Issue
Editor's Note - This issue of MedicinMan is dedicated to the memory of Dr. Tarun Gupta, TG as he was fondly called. Executive Editor, Salil Kallianpur, dear friend Subrato Banerjee and long-time MedicinMan patron Vivek Hattangadi, pen their tributes to TG.
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Hot topics
Crafting a Digital Strategy
A Digital-in-pharma special issue. Announcement for ACG-MedicinMan's "Pharmaceutical Marketing in the New Age" conference to be held in March 2018
Trump Tariff and the Trade Turbulence – A Salil Kallianpur BlogÂ
Impact of Trump’s 100% tariff on imported patented/innovative drugs...
Interview with Ajit Singh, Chairman, ACG
Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan
The Pill is Now a Commodity – Can ‘Beyond the Pill’ Models Work in India?
The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered.
The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model.
Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison.
‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product.
Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it.
A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it.
The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).
Philippe Gautron Takes on Role as Senior Vice President & Business Head – APAC at Glenmark Pharmaceuticals
Ho Chi Minh City, Vietnam, March 2026 — Glenmark...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Newsletter
Get important news delivered directly to your inbox and stay connected!